Molecular Partners AG (CH:MOLN)
:MOLN
Top Page
Molecular Partners AG
(MOLN)
Select Model
Select Model
Rating:45Neutral
Price Target:
CHF3.00
▼(-12.02% Downside)
Action:ReiteratedDate:03/19/26
The score is primarily weighed down by weak financial performance, marked by collapsed revenues, heavy losses, and sustained negative cash flows despite low leverage. Technicals are only moderately supportive due to a better longer-term trend but soft near-term momentum. Valuation is also pressured because the company is loss-making (negative P/E) and no dividend yield is indicated.
Positive Factors
Proprietary DARPin platform & partnerships
Molecular Partners’ proprietary DARPin platform is a durable competitive asset: its modular, multi-specific design creates differentiated therapeutic candidates and makes the company an attractive partner. Platform-driven projects can generate recurring licensing, milestone, and royalty economics that support long-term value capture even without internal commercialization.
Negative Factors
Collapsed revenues and heavy losses
Revenue collapse to near-zero by 2025 and reversion to heavy losses after 2022 undermine the firm’s capacity to self-fund R&D. Persistent negative profitability increases reliance on external partners or financing, magnifies execution risk for clinical programs, and makes long-term product development outcomes highly binary.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary DARPin platform & partnerships
Molecular Partners’ proprietary DARPin platform is a durable competitive asset: its modular, multi-specific design creates differentiated therapeutic candidates and makes the company an attractive partner. Platform-driven projects can generate recurring licensing, milestone, and royalty economics that support long-term value capture even without internal commercialization.
Read all positive factors
Molecular Partners AG (MOLN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF134.85M
Dividend YieldN/A
Average Volume (3M)17.77K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue Growth-100.00%
EPS Growth14.45%
CountryCH
Employees158
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.34
Shares Outstanding40,374,640
10 Day Avg. Volume21,556
30 Day Avg. Volume17,775
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)1.57
Price to Sales (P/S)0.00
P/FCF Ratio-2.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF15.00Price Target Upside339.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.37
Revenue Forecast (FY)CHF5.40M
Molecular Partners AG Business Overview & Revenue Model
Company Description
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is ...
How the Company Makes Money
Molecular Partners primarily makes money through (1) collaboration and licensing arrangements and (2) any grants or other operating income related to research activities; product sales revenue is typically not a meaningful source for a clinical-st...
Molecular Partners AG Earnings Call Summary
Earnings Call Date:Mar 06, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Aug 31, 2026
Earnings Call Sentiment Positive
Molecular Partners demonstrated significant progress in advancing their pipeline, particularly with the radio DARPin franchise and T cell engager 533, while maintaining a strong financial position. However, the discontinuation of the Novartis collaboration and resulting revenue impact were notable drawbacks.Positive Updates
Successful Execution of 2024 Program Goals
Molecular Partners advanced their radio DARPin franchise with the lead compound DLL3 targeting 712 passing all IND-enabling studies, ready for clinical trials. They selected mesothelin as a new target and expanded their collaboration with Orano Med, securing 10 slots for Lead-212 isotope.
Negative Updates
Novartis Collaboration Setback
The collaboration with Novartis was not continued as the targets did not progress as expected. This decision was mutual and based on strategic interests.
Read all updates
Q4-2024 Updates
Positive
Negative
Successful Execution of 2024 Program Goals
Molecular Partners advanced their radio DARPin franchise with the lead compound DLL3 targeting 712 passing all IND-enabling studies, ready for clinical trials. They selected mesothelin as a new target and expanded their collaboration with Orano Med, securing 10 slots for Lead-212 isotope.
Read all positive updates
Company Guidance
During the Molecular Partners Fourth Quarter and Full Year 2024 Results Call, several notable metrics and guidance were provided. For the fiscal year 2024, the company reported revenues of CHF 5 million, exclusively from the Novartis collaboration. Operating expenses were CHF 66 million, within the guidance range of CHF 65 million to CHF 70 million, with 74% allocated to R&D. The net financial result benefited from high interest rates, contributing to an end-of-year cash balance of CHF 149 million, down from CHF 187 million the previous year, resulting in a cash burn of CHF 54 million. Looking ahead to 2025, Molecular Partners anticipates operating expenses between CHF 55 million and CHF 65 million, excluding potential partnership payments. The company is focused on advancing its radio DARPin programs, particularly MP0712, with expectations to start clinical trials and provide initial imaging data by the end of the year, while also progressing with its T cell engager program, MP0533, in AML, with new dosing amendments and outcomes expected by year-end.Molecular Partners AG Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 4.97M | 7.04M | 189.56M | 9.33M |
| Gross Profit | -2.15M | -42.53M | -40.81M | 138.81M | -46.39M |
| EBITDA | -53.26M | -51.63M | -59.52M | 119.00M | -60.66M |
| Net Income | -61.65M | -54.04M | -61.98M | 117.85M | -63.78M |
Balance Sheet | |||||
| Total Assets | 102.11M | 158.53M | 198.35M | 262.26M | 172.67M |
| Cash, Cash Equivalents and Short-Term Investments | 93.06M | 149.44M | 186.89M | 249.14M | 132.81M |
| Total Debt | 3.64M | 2.44M | 3.65M | 4.85M | 6.04M |
| Total Liabilities | 21.77M | 16.89M | 21.92M | 27.09M | 65.38M |
| Stockholders Equity | 80.33M | 141.64M | 176.43M | 235.17M | 107.29M |
Cash Flow | |||||
| Free Cash Flow | -50.24M | -59.97M | -59.81M | 117.15M | -92.26M |
| Operating Cash Flow | -49.53M | -59.25M | -59.01M | 118.57M | -90.95M |
| Investing Cash Flow | 70.82M | 40.49M | 44.64M | -101.12M | -22.24M |
| Financing Cash Flow | -1.15M | 14.43M | -1.17M | -1.57M | 50.58M |
Molecular Partners AG Technical Analysis
Positive
3.41
Price Trends
3.52
Negative
3.41
Negative
3.18
Positive
Market Momentum
-0.12
Positive
48.53
Neutral
37.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:MOLN, the sentiment is Positive. The current price of 3.41 is above the 20-day moving average (MA) of 3.37, below the 50-day MA of 3.52, and above the 200-day MA of 3.18, indicating a neutral trend. The MACD of -0.12 indicates Positive momentum. The RSI at 48.53 is Neutral, neither overbought nor oversold. The STOCH value of 37.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:MOLN.
Molecular Partners AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | CHF310.84M | -9.69 | ― | ― | 744.64% | ― | |
48 Neutral | CHF236.25M | -0.98 | -301.13% | ― | -56.85% | -186.55% | |
45 Neutral | CHF134.85M | -2.50 | -51.05% | ― | -100.00% | 14.45% | |
45 Neutral | CHF885.27M | -8.17 | ― | ― | 229.23% | 63.47% |
* Healthcare Sector Average
CH:MOLN
Molecular Partners AG
3.34
0.25
8.09%
CH:IDIA
Idorsia Ltd
3.50
2.50
251.05%
CH:NWRN
Newron Pharmaceuticals SpA
14.94
8.72
140.19%
CH:SANN
Santhera Pharmaceuticals Holding
16.64
3.38
25.49%
CH:XLS
Xlife Sciences Ltd.
21.50
2.50
13.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.